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Piper carpunya Ruiz & Pav. (Piperaceae) is a perennial aromatic shrub of Amazonian area of Ecuador and Peru, belonging to
the ethnomedicine of these countries. The traditional preparations of the crude drug (fresh leaves used topically as is, and dried
leaves in infusions or decoctions) are known for anti-inflammatory, antiulcer, antidiarrheal, antiparasitic effects, andwound healing
properties. In light of this traditional evidence, chemical composition (GC-MS) and biological activity, i.e., antioxidant, antifungal
(yeast) capacities, and genotoxicity, of Amazonian P. carpunya leaf essential oil (EO) have been investigated in order to valorize
some of the putative ethnomedical effects. The EO was obtained through steam distillation of fresh leaves (yield: 7.6 g/kg [0.76%];
refractive index at 20∘C: 1.49; density: 0.928 g/mL). Chemical characterization performed through GC-MS evidenced the presence
of 21 compounds (96.2% of the total). The most abundant constituents were piperitone (26.2%), limonene (9.5%), elemicin (7.2%),
and 𝛽-phellandrene (5.6%). In vitroDPPH antioxidant assay showed a weak radical scavenging ability (IC50) if compared to positive
control. Low bioactivity of the EO was also demonstrated against yeast, but it showed an interesting synergistic activity (FIC index
of EO+fluconazole) against Candida sp. strains. Ames test evidenced the safety of the EO concerning genotoxicity.
1. Introduction
This study is part of a large research project characterized
by the biodiversity mapping of Amazonian Ecuador flora
belonging to ethnomedical traditional uses through chemical
and biological characterization of EOs [1, 2].
Since most of the plant species used as traditional health
remedies are characterized by flavours and aromatic smell,
the study of EOs is one of the best strategies to draw a
research profile matching biodiversity and phytomedicine.
Piper carpunya Ruiz & Pav (syn. Piper lenticellosum C.D.C.)
is a perennial shrub belonging to the Piperaceae botan-
ical family, widely distributed in the Amazonian area of
Colombia, Ecuador and Peru. Traditionally, the aromatic
Piper species are used in Latin America as analgesics in
pain management, toothache and wound treatments [3]. P.
carpunya has instead more specific and slightly different
ethnomedical applications. In fact, fresh and dried leaves
of P. carpunya, mainly known with the vernacular name of
“guaviduca,” are widely used in traditional preparations (i.e.,
decoctions or direct application) in tropical and subtropical
South American Countries to treat generic inflammations
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(i.e., bronchitis and fever), topical infections (i.e., vaginal
candidiasis), gastrointestinal disorders (i.e., ulcers, diarrhea
and parasitic intestinal infections) and generic digestive
problems [4, 5].
Notmany papers were published about P. carpunya. Some
of them deal with the above mentioned uses: for example, the
capacity of traditional preparations of P. carpunya to protect
in vivo against gastric disorders induced by gastric harmful
drugs or Helicobacter pylori infections [4]. Other papers,
instead, reported the phytochemical composition of the EO
obtained by the leaves of P. carpunya, mainly characterized
by terpenes [6–8].
Despite the abundant scientific reports about Piper
species, the knowledge about P. carpunya EO is still scarce.
Therefore, the aim of the present paper is to characterize the
EO obtained from the leaves of the Ecuadorian P. carpunya
and to evaluate its biological activities. A phytochemical
fingerprint was performed through gas chromatography cou-
pledwithmass spectrometry (GC–MS) in order to chemically
characterize the EO. It was subsequently tested in vitro
for antioxidant and antimicrobial evaluations, also through
synergistic and time-killing assays, in order to verify the
traditional uses assuming that the bioactivities were mainly
due to the terpene fraction. For this reason, the most abun-
dant terpene compounds detected in the EO were also tested
for the same bioactivities, trying to identify those molecules
putatively responsible of the biological properties. Finally, in
order to assess the safety of the P. carpunya EO, Ames test
with S. typhimurium strains was performed to check possible
genotoxic implications.
2. Materials and Methods
2.1. Plant Material and Essential Oil. Piper carpunya Ruiz
& Pav leaves of adult plants from three different stocks
were collected in November 2014 at balsamic period (before
flowering) from wild shrubs growing in the outskirts of the
Kutuku Experimental Station, province of Morona Santiago,
Ecuador. After harvesting, the P. carpunya leaves were in situ
immediately subjected to hydrodistillation using a portable
Clevenger-type apparatus. The EO was extracted by steam
distillation (3 h) of P. carpunya fresh leaves (8 kg) using
deionized water (8 L). The refractive index was measured
at 20∘C using the refractometer Abbe 60, while density was
checked using a densitometer DCE-DB 600. The essential
oil samples were then stored in amber airtight glass vials at
18±0.5∘C to prevent degradations prior to analyses. A speci-
men of P. carpunya EO was deposited at Salesian Polytechnic
University (Quito, Ecuador) (voucher specimen: HUPS-pi-
002). Aliquots of the EO samples were then transferredmain-
taining the storage conditions of the original specimen to the
Department of Life Sciences and Biotechnology, University of
Ferrara (Ferrara, Italy) for chemical and biological analyses.
2.2. Chemicals. All solvents and chemicals employed for
chemical and biological analyses were chromatographic
grade. Solvents, pure compounds, employed as positive
reference, were all purchased from Sigma–Aldrich Italy
(Milano, Italy; www.sigmaaldrich.com).
2.3. Gas Chromatographic Coupled with Mass Spectrom-
etry (GC-MS) and Flame Ionization Detection (GC-FID)
Analyses. P. carpunya EO was analyzed by a Varian GC-
3800 gas chromatograph equipped with a Varian MS-4000
mass spectrometer using electron impact and hooked to
NIST library. A Varian FactorFour VF-5ms poly-5% phenyl-
95%-dimethylsiloxane column (internal diameter, 0.25 mm;
length, 30m; film thickness, 0.15 𝜇m)was used.The following
conditions were adopted: injector temperature 250∘C, carrier
(Helium) flow rate 1 mL/min and split ratio 1:50. Oven
temperature was as follows: from 55 to 100∘C at a rate of
1∘C/min, from 100 to 250∘C at a rate of 5∘C/min and then
kept constant at 250∘C for 15 min. One microliter of sample
dissolved in methanol was injected. For the calculation of
the relative retention time (RI), a mixture of C8 to C32
hydrocarbons (Sigma-Aldrich), was previously injected into
the system applying the same method used to analyze
EO. The constituents of the volatile oil were identified by
comparing their GC relative retention times, RI and the MS
fragmentation pattern with those of other EOs of known
composition, with pure compounds and by matching the
MS fragmentation patterns, as well as retention indices, with
the above mentioned mass spectra libraries and with those
in the literature [12, 13]. The MS conditions were ionization
voltage, 70 eV; emission current, 10 𝜇Amp; scan rate, 1
scan/s; mass range, 29–400 Da; trap temperature, 150∘C and
transfer line temperature, 300∘C. For the quantitative anal-
ysis a ThermoQuest GC-Trace gas-chromatograph equipped
with a FID detector and the same column above described
were used. The operating conditions for gas chromatograph
were reported above. FID temperature was 250∘C. The oil
percentage composition was performed by the normalization
method from the GC peak areas, without using correction
factors.
2.4. Biological Activities. Antioxidant properties and antimi-
crobial activity against different strains of human pathogen
yeast Candida albicans were performed using the EO and
the most abundant compounds, as putative most responsible
agent of biological properties. With specific reference to
antimicrobial activities, synergistic interactions were also
checked in order to explore the possibility of increasing the
biological efficacy employing a formulation with different
ratio of EO and fluconazole as synthetic drug commonly used
in pharmaceuticals for treating candidiasis. Ames test was
finally performed to assess safety of P. carpunya EO for what
concerns genotoxicity. All the bioactivities were performed
using proper negative and positive controls [14]. All the data
reported are the average of three determinations of three
independent experiments.
2.4.1. DPPH Antioxidant Activity: High-Throughput RDSC
Assay. A DPPH (2,2-diphenyl-1-picrylhydrazyl) stock solu-
tion (0.208 mM in 50% ethanol) was prepared and kept
at 4∘C in the dark, according to the method reported for
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High-Throughput RDSC assay [15]. Ethanol stock solutions of
Trolox (50%) (160 𝜇M), P. carpunya EO (2 mg/mL), piperi-
tone, limonene, 1,8-cineole, methyleugenol and thymol (20
mg/mL) were also prepared and stored at 4∘C. Starting from
the stock solutions, 96-well microplates were filled with 200
𝜇L/well of the following samples progressively less concen-
trated (dilution ratio 1:2): (i) P. carpunya EO +DPPH ethanol
solution 50% (100 𝜇L + 100 𝜇L); (ii) Piperitone (limonene,
1,8-cineole, methyleugenol) + DPPH ethanol solution 50%
(100 𝜇L + 100 𝜇L); (iii) Trolox (or thymol) + DPPH ethanol
solution 50% (100 𝜇L + 100 𝜇L; as positive control); (iv)
DPPH ethanol solution 50% + ethanol 50% (100 𝜇L + 100
𝜇L; as negative control); (v) ethanol solution 50% (200 𝜇L;
as blank). The concentration ranges were as follows: 7.8-1000
𝜇g/ml for P. carpunya EO, thymol, limonene, methyleugenol
and 1,8-cineole; 78-10000 𝜇g/ml for piperitone; 0.6-80.0 𝜇M
for Trolox and each concentration was tested in triplicate.
0.104 𝜇M was the DPPH concentration in all wells. The 96-
well microplates were then incubated in agitation (100 rpm)
for 40min at room temperature in the dark. After incubation,
the 96-microwells plates were checkedwithmicroplate reader
(Microplate Reader 680 XR, Biorad) at 515 nm. Antioxidant
activities were expressed as IC50 (concentration providing
DPPH 50% inhibition) and calculated from inhibition curves
obtained by plotting inhibition percentage against EO and
pure compounds concentration and as 𝜇mol/g of Trolox
equivalent [16]. All experiments were assessed in triplicate
and values were reported as mean ± SD (standard deviation).
2.4.2. Antimicrobial Activity against Candida spp.: Microbroth
Dilution Method. Antimicrobial tests were carried out by
the microbroth dilution method using three Candida spp.
strains: Candida albicans (AIDS6; fluconazole resistant clin-
ical strain isolated from a HIV patient), Candida glabrata
(FLU 43976; resistant to fluconazole), and Candida albicans
(ATCC 24433; from American Type Culture Collections;
sensitive to fluconazole). The Minimum Inhibitory Concen-
tration (MIC) was determined through the microdilution
method in accordance with “Clinical and Laboratory Stan-
dards Institute/National Committee for Clinical Laboratory
Standards” (CLSI / NCCLS). P. carpunya EO and fluconazole,
used as positive control, were diluted on 96-well microplate,
obtaining 8 different concentrations (from 48.8 to 6250
𝜇g/mL and from 0.5 to 64 𝜇g/mL respectively), tested in trip-
licate. In each microwell, Candida strains were inoculated to
reach a final concentration of 2.5x103 CFU/mL and incubated
for 48 hours at 30∘C with the EO samples and fluconazole at
different concentrations; the final total volume in each well
was 200𝜇L [17].The Candida culture media were RPMI-1640
supplemented with 3-(N-morpholino) propanesulfonic acid
(MOPS) at pH 7.0; Tween 20 (0.2%; Sigma-Aldrich, St. Louis,
MO, USA) was added to improve the solubility. The MIC
was determined by direct observation of the turbidity of the
culture medium. The MIC values were represented by the
lowest concentration at which no turbidity of the medium
was observed.Then, theMinimumFungicidal Concentration
(MFC) was checked by transferring 10 𝜇L of the culture
medium of each well into a new well with Saboraud Dextrose
Agar (SDA) and incubating at 30∘C for 48 hours. The final
volume in each well was 200 𝜇L. The MFC was considered
as the lowest concentration that did not determine Candida
growth. Culturemedia andTween 20 (0.2%) solution (200𝜇L)
were used as negative control.
2.4.3. Synergy Test. Synergistic evidence of anti-Candida
activity was checked through checkerboard test using EO
and fluconazole [18] at the same experimental conditions
employed for MIC and MFC determination. Eight serial
dilutions (1:2) of P. carpunya and fluconazole were used
to build an 8x8 square matrix that allowed to assay 64
different combinations of EO and drug concentration in one
96-well microplate. The X-axis of the matrix corresponded
to the EO concentration gradient dilutions (range: 48.8 -
6250 𝜇g/mL); the Y-axis, instead, was represented by the
fluconazole gradient dilutions (range: 0.5 - 64 𝜇g/mL). The
synergistic activity was expressed as fractional inhibitory
concentration (FICindex) and was calculated as follows:
FICindex = FICEO + FICfluconazole (1)
where FICEO = MICEO+fluconazole/MICEO; FICfluconazole =
MICfluconazole+EO/MICfluconazole.
The same procedures to detect FICindex for MIC values
were performed to check possible synergistic effect for MFC.
Legend: FICindexvalues ≤ 0.5 means the presence of
synergistic effect; 0.5<values≤2 means additive or indifferent
effect; values > 2 means antagonistic effect [18].
2.4.4. Time Killing. To confirm the synergistic activity, a
time-killing fungicide curve was performed [9, 19]. Based
on the synergistic results, C. albicans AIDS6 strain was used
to test P. carpunya EO and fluconazole combination. AIDS6
strain was grown in tubes filled with Sabouraud dextrose
broth (SDB, LTD Oxoid, Basingstoke, Ampshire, England)
for 24 h at 28∘C. Then, AIDS6 cultures were centrifuged,
washed and resuspended to reach a concentration of 2.5 ×
105 CFU/mL in RPMI-1640 buffered with MOPS at pH 7.0
and incubated at 28∘C.The following four sampleswere tested
in triplicate: (i) P.carpunya EO (MIC value); (ii) flucona-
zole (MIC value); (iii) P. carpunya EO and fluconazole in
combination (best FICindex concentrations); (iv) P. carpunya
EO and fluconazole in combination (the first value higher
than the best FICindex concentrations). Tween 20 (0.2%) has
been added to increase the solubility of the EO. The same
procedure was used to prepare the negative controls (AIDS6
culture and Tween 20, 0.2%). Each sample was incubated
at 30∘C and gently shacked (100 rpm). Cell growth was
monitored at time 0, after 1h, 2h, 4h, 6h and 24h; 100 𝜇L of the
AIDS6 culture at each monitoring time was serially diluted
(dilution range 1-105). One hundred microlitres (100𝜇L) of
each dilution was seeded in Petri dishes (90 mm diameter)
containing SDA and incubated for 48 h at 30∘C in the dark.
After incubation, the grown AIDS6 colonies were counted
[10].
2.4.5. Genotoxicity Assay (Ames Test). To investigate the
possible genotoxic activity of P. carpunya EO, Ames test
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employing the Salmonella typhimurium strains TA97a, TA98,
TA100 and TA1535 was performed [11, 20]. An inoculum of
each bacterial strain culture (100𝜇L) was added to 20 ml of
Nutrient Broth and incubated at 37∘C in an orbital shaker
(120 rpm) until a microbial concentration of approximately
2 x 108 bacteria/ml is reached. Petri dishes (90 mm diameter)
containing a basic agar and low concentrations of histidine
and biotin were topped with 2 ml of molten agar (45∘C)
prepared with 100 𝜇L of fresh bacterial culture and 100 𝜇L
of EO diluted in DMSO (dilution range: 0.1-10 mg/plate).
The mutagenic activity was determined on the basis of
the counted colonies of each Salmonella strain in plates
treated with different concentrations of P. carpunya EO with
metabolic activation [addition of 500 𝜇L of S9 mix dissolved
in a solution of KCl (33mM), NADPH (4mM), MgCl2
(8mM), and glucose-6-phosphate (5mM)] or, alternatively,
without metabolic activation (500 𝜇L of 7.4 pH phosphate
buffer). Positive controls were set up with 2 𝜇g/plate of 2-
aminoanthracene for all Salmonella strains cultured with
metabolic activation; and 2 𝜇g/plate of 2-nitrofluorene for
strains TA97a, TA98, TA1535, and 1 𝜇g/plate of sodium azide
for TA100 strain, for Ames test performed without activation
by S9 mix. Negative controls were set up with 100 𝜇L of
DMSO, both with and without S9 mix. The plates were
incubated for three days at 37∘C and colonies were counted
(Colony Counter 560 Suntex, Antibioticos, Italy). All the
mutagenic assays were performed in triplicate and the results,
integrated by statistical analyses, were considered positive
when the number of colonies of revertants was at least double
if compared to those of the negative controls [11, 20].
2.5. Statistical Analyses. All the experiments were performed
in triplicate. IC50values were assessed by logarithmic regres-
sion curves with 95% confident limits. Relative standard devi-
ations and statistical significance (Student’s T test; p±0.05)
were calculated using software STATISTICA 6.0 (StatSoft
Italia srl, Vigonza, Italy).
3. Results
3.1. Chemical Fingerprinting of P. carpunya Essential Oil.
Fresh leaves of P. carpunyawere collected during the balsamic
period (before flowering) and directly steam-distilled to
obtain the essential oil. The distillation yield was of 0.76%
(w/w%), the refractive index of 1.49 ± 0.02, and the density
of 0.928 ± 0.040 g/mL. The colour was pale yellow, and the
smell was persistent and strongly aromatic, similar to that of
pepper. GC-MS analyses were performed to determine the
chemical characterization of the essential oil: fortytwo (42)
compounds (96.2% of the total) were identified. Piperitone
(26.2%), limonene (9.5%), elemicin (7.2%), 𝛽-phellandrene
(5.6%), methyleugenol (4.5%), and 1,8-cineole (4.0%) were
themost abundant (Table 1): their experimental mass-spectra
were reported in Figure 1.
3.2. Antioxidant Activity of P. carpunya Essential Oil: DPPH
Assay. The DPPH assay was performed to test the antioxi-
dant capacity of P. carpunya EO and of the main compounds
detected in the phytocomplex. The results were compared
to those achieved with positive control Trolox and thymol,
taken as reference terpene with well-known antioxidant
activity (Table 2) [21].The antioxidant activity of P. carpunya
EOwasmoderately interesting with values very far from both
pure compound thymol and Trolox. Piperitone, limonene,
1,8-cineole, and methyleugenol were tested alone as pure
compounds: only the last was active, but the activity of EO
could not be explained by these molecules. Their mixture or
other minor compounds could be responsible of the DPPH
capacity.
3.3. Antimicrobial Activity against Candida sp.: Minimum
Inhibitory Concentration. The possible synergistic effects of
EO and fluconazole (the first-line agent in the candidiasis
treatment) were tested at different doses to evaluate different
mutual relations. The fractional inhibitory concentration
index (FICindex) was used as synergy evaluation parameter
and was considered synergistic at values less or equal to 0.5
[18]. Table 3 summarizes the results obtained, the activity of
the antifungal fluconazole, and the EO tested individually and
in combination.TheMIC andMFC values for P. carpunya EO
were found to be 781 𝜇g/mL and 1562 𝜇g/mL, respectively,
for C. albicans (ATCC 24433); the same results (MIC: 1562
𝜇g/mL; MFC: 1562 𝜇g/mL) were checked for C. albicans
(AIDS6) and C. glabrata (FLU 43976). C. glabrata (FLU
43976) and C. albicans (ATCC 24433) showed the same
sensitivity if treated with fluconazole (MIC: 32 𝜇g/mL; MFC:
32 𝜇g/mL).C. albicans (AIDS6) showed instead that it ismore
resistant (MIC: 128 𝜇g/mL; MFC: 128 𝜇g/mL).
3.4. Sinergy and Time Killing . The presence of synergistic
effects of a mixture characterized by different concentrations
of P. carpunya EO and fluconazole (1:1) was checked on the
three Candida sp.strains.TheMIC andMFC results that gave
the best FICindex data are reported in Table 3. The MIC and
MFC values obtained with EO plus fluconazole solution (EO:
391 𝜇g/mL; fluconazole: 4 𝜇g/mL) were 4-folds lower than
those displayed by the sole EO for both C. albicans (AIDS6)
and C. glabrata (FLU 43976). The MIC and MFC obtained
with the sole fluconazole were 32-folds higher than those
achieved with the mixture of EO and synthetic drug for C.
albicans (AIDS6), while they were 8-folds for C. glabrata
(FLU 43976). No synergistic effects were evidenced for C.
albicans (ATCC 24433).
The synergistic effect of P. carpunya EO with fluconazole
was confirmed by time-kill curve experiments performed
employing the C. albicans (AIDS6) strain since it showed the
best FICindex. The strain (cell density of 1–5 x 10
5 CFU/mL)
was exposed to MIC values of P. carpunya EO, of fluconazole
alone and of the EO-fluconazole mixture that displayed the
best FICindex (Figure 2). Time-kill analysis showed that the
mixture of P. carpunya EO and fluconazole almost totally
inhibited the growth of the Candida strain over 24 hours
compared to the negative control. In particular, after only
2 hours of exposure, the microbial growth was almost
completely reduced to values similar to those detected after
24 h.
Evidence-Based Complementary and Alternative Medicine 5
Table 1: Chemical characterization of P. carpunya EO performed by GC-MS and GC-FID analyses.
N∘ Compounda IDMethodb RI calcc RI litd %e
1 𝛼-thujene RI, MS 920 924 0.2
2 𝛼-pinene Std 927 932 3.4
3 sabinene Std 965 969 1.4
4 𝛽-pinene Std 970 974 1.1
5 myrcene RI, MS 985 988 1.4
6 𝛿-2-carene RI, MS 995 1001 0.2
7 𝛼-phellandrene RI, MS 1003 1002 1.1
8 𝛿-3-carene RI, MS 1004 1008 0.3
9 𝛼-terpinene RI, MS 1012 1014 3.9
10 p-cymene RI, MS 1019 1020 3.4
11 limonene Std 1023 1024 9.5
12 𝛽-phellandrene RI, MS 1024 1025 5.6
13 1,8-cineole Std 1026 1026 4.0
14 trans-E-ocimene RI, MS 1041 1044 0.2
15 𝛾-terpinene RI, MS 1051 1054 3.0
16 cis-sabinenehydrate RI, MS 1065 1060 0.2
17 linalool Std 1099 1095 1.5
18 1,3,8-p-menthatriene RI, MS 1109 1110 0.3
19 3-thujen-2-ol RI, MS 1168 1167 2.4
20 terpinen-4-ol Std 1174 1174 0.3
21 neoisodihydrocarveol RI, MS 1233 1229 0.6
22 cuminaldehyde RI, MS 1237 1238 0.3
23 piperitone Std 1250 1249 26.2
24 𝛼-terpinen-7-al RI, MS 1279 1283 1.3
25 safrole RI, MS 1283 1285 2.2
26 thymol Std 1293 1289 0.9
27 carvacrol RI, MS 1300 1298 0.7
28 𝛼-terpinylacetate RI, MS 1354 1343 1.3
29 eugenol Std 1361 1356 0.9
30 𝛼-copaene RI, MS 1374 1374 0.4
31 𝛽-elemene RI, MS 1387 1389 0.2
32 𝛽 -longipinene RI, MS 1397 1401 0.2
33 methyleugenol RI, MS 1401 1403 4.5
34 𝛽-caryophyllene Std 1408 1417 0.3
35 p-cymen-7-ol acetate RI, MS 1422 1421 1.5
36 germacrene D RI, MS 1474 1485 1.4
37 bicyclogermacrene RI, MS 1488 1500 1.2
38 elemicin RI, MS 1551 1555 7.2
39 trans-nerolidol Std 1561 1561 0.2
40 spathulenol RI, MS 1574 1577 0.7
41 globulol RI, MS 1583 1585 0.5
42 viridiflorol RI, MS 1592 1592 0.1
Total 96.2
Hydrocarbon monoterpenes 35.0
Oxygenated monoterpenes 41.2
Hydrocarbon sesquiterpenes 3.7
Oxygenated sesquiterpenes 1.5
Phenylpropanoids 14.8
a Compounds are listed in order of elution from a Varian VF-5ms column.
b Identification method adopted for each compound.
c Retention indices calculated on a Varian VF-5ms column.
d Relative area percentage (peak area relative to total peak area%).
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Figure 1: Experimental mass-spectra of (a) limonene, (b) 𝛽-phellandrene, (c) 1,8-cineole, (d) piperitone, (e) methyeugenol and (f) elemicin.
3.5. Ames Test: Genotoxic Activity. In order to assess the geno-
toxic effect of P. carpunya EO, induction or suppression of
revertant colonies was examined in Salmonella typhimurium
strains. The number of spontaneous revertants of the four
strains with or without S9 metabolic activation was deter-
mined in each set of experiment and indicated as untreated
sample in Table 4.
Different concentrations of the P. carpunya EO did not
show any genotoxic effect on SalmonellaTA97a, TA98, TA100
and TA1535 strains. Just two doses exhibited mutagenic
activity (t/c ≥ 2) against TA1535 and TA97a strain, without
metabolic activator (S9 mix) at 500 and 1000 𝜇L/plate,
respectively. On the other hand, in presence of S9 mix
microsomal fraction, the only TA1535 strain evidenced a
mutagen sensitivity in presence of the EO both at 500
and 1000 𝜇L/plate. In any case, no dose-response trend
was observed suggesting the conclusion of the safety of P.
carpunya EO with regard to genotoxicity.
4. Discussion
For the past several years our research group has been
involved in studying Amazonian medicinal plants through
Evidence-Based Complementary and Alternative Medicine 7
0.0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100.0
t. zero 1 h 2 h 4 h 6 h 24 h
C
el
l g
ro
w
th
 (%
 v
s n
eg
at
iv
e c
on
tro
l)
Time
C - OE FLU FIC index
Figure 2: Time-killing curves of MICs (Minimum Inhibitory Concentrations, 𝜇g/mL) of P. carpunya (EO), fluconazole (FLU) and their
combination (FIC index) against C. albicans (AIDS6).
Table 2: Antioxidant properties of P. carpunya EO evaluated by DPPH assay. The values, expressed as IC50, were compared to thymol,
piperitone, limonene, 1,8-cineole, methyleugenol and Trolox.
DPPH
Samples IC501 (𝜇g/mL) TEAC (mmol TE/g)
P. carpunya EO 159.80 ± 3.40 71.88 ± 1.53
piperitone 2278.00 ± 31.74 2.61 ± 0.32
limonene >1000 <0.89
1,8-cineole >1000 <2.05
methyleugenol 602.00±5.59 17.87±0.56
thymol 70.80 ± 1.51 160.02 ± 3.45
trolox 3.97 ± 0.40 --
1
IC50: concentration corresponding to the 50% of the bioactivity;
2 TEAC: Trolox equivalent (TE) antioxidant capacity.
Table 3: Synergistic effect of P. carpunya EO employing fluconazole as synthetic active drug against Candida sp.
FICindex MIC Findex MCF EO FLU
(EO+FLU) (EO+FLU) MIC MFC MIC MFC
C. albicans (AIDS6) 0.281∗(391+4)∗∗
0.281∗
(391+4)∗∗ 1562 1562 128 128
C. glabrata (FLU 43976) 0.375∗(391+4)∗∗
0.375∗
(391+4)∗∗ 1562 1562 32 32
C. albicans (ATCC 24433) 1.063(781+2)∗∗
0.016
(1562+0.5)∗∗ 781 1562 32 32
FICindex: fractional inhibitory concentration index; FICindex ≤ 0.5 means the presence of synergistic effect; 0.5≤FICindex ≤2 means additive or indifferent
effect; FICindex > 2 means antagonistic effect[9, 10].
∗ Values displaying a synergistic effect.
∗∗ Concentration in 𝜇g/mL of EO and FLU, respectively, corresponding to FICindex.
MIC: Minimum Inhibitory Concentration (𝜇g/mL);MFC: Minimum Fungicidal Concentration (𝜇g/mL).
EO: P. carpunya EO; FLU: fluconazole.
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Table 4: Ames test performed to check the genotoxic safety (no. of revertants induced) of P. carpunya EO.The results are expressed as average
of number of colonies per plate, followed by the standard deviation (sd). t/c means the ratio between the number of colonies of Salmonella
strains grown in presence of EO and those of the negative control (DMSO). If t/c ratio is ≥ 2, following a dose-response trend, the extract can
be considered as potential mutagen [11].
Dose level (𝜇L/plate) TA97a TA98 TA100 TA1535
Average ± s.d. t/c Average ± s.d. t/c Average ± s.d. t/c Average ± s.d. t/c
-S9
10 149.0 ± 7.6 1.15 24 ± 4.2 0.79 89 ± 9.9 0.81 4.0 ± 2.8 0.57
50 110.5 ± 10.1 0.85 20 ± 5.7 0.66 87 ± 1.4 0.79 10.5 ± 0.7 1.50
100 149.5 ± 8.5 1.15 25 ± 8.4 0.82 77 ± 12.7 0.70 3.0 ± 1.4 0.43
500 65.0 ± 9.7 0.50 29.5 ± 2.1 0.97 46.0 ± 2.8 0.42 36 ± 3.2 5.14∗
1000 546.0 ± 31.1 4.20∗ 26.0 ± 2.8 0.85 8.5 ± 3.5 0.08 8.0 ± 11.3 1.14
5000 12.5 ± 0.7 0.10 25.5 ± 19.1 0.84 19 ± 24.0 0.17 0.0 ± 0.0 0.00
10000 0.0 ± 0.0 0.00 10.5 ± 6.4 0.34 0.0 ± 0.0 0.00 0.0 ± 0.0 0.00
DMSO (100 𝜇L)( 130.0 ± 14.2 1.00 30.5 ± 0.7 1.00 110 ± 7.1 1.00 7.0 ± 2.8 1.00
2-Nitrofluorene (2 𝜇L) 1554 ± 113.3 12.00 716 ± 75.0 23.48 -- -- 47 ± 1.8 6.71
Sodium azide (1 𝜇L) -- -- -- -- 688 ± 72.0 6.25 -- --
+S9
10 67.5 ± 8.4 0.39 44 ± 2.8 1..06 106 ± 14.1 1.15 9.5 ± 0.7 1.00
50 112.5 ± 9.7 0.66 34 ± 4.2 0.82 84 ± 5.7 0.91 12 ± 1.4 1.26
100 112.5 ± 8.1 0.66 43 ± 14.1 1.04 87 ± 26.9 0.95 11 ± 4.2 1.16
500 157.5 ± 12.1 0.92 35 ± 0.0 0.84 76.5 ± 9.2 0.83 38.5 ± 6.8 4.05∗
1000 175.5 ± 10.2 1.03 37.5 ± 6.4 0.90 64.5 ± 9.2 0.70 23.5 ± 33.2 2.47∗
5000 0.0 ± 0.0 0.00 25 ± 7.1 0.60 22.5 ± 12.0 0.24 0.0 ± 0.0 0.00
10000 0.0 ± 0.0 0.00 14 ± 4.2 0.34 6 ± 5.7 0.07 0.0 ± 0.0 0.00
DMSO, 100 𝜇L 171.0 ± 6.8 1.00 41.5 ± 2.1 1.00 92 ± 2.8 1.00 9.5 ± 0.7 1.00
2-Aminoanthracene (2𝜇L) 896 ± 10.4 5.24 932 ± 98.0 22.46 912 ± 95.0 9.91 168 ± 18.0 17.68
+S9: experiments performed with metabolic activation (S9 mix).
-S9: experiments performed without metabolic activation (S9 mix).
DMSO: dimethylsulfoxide, negative control; 2-aminoanthracene: positive control for experiments with S9; 2-nitrofluorene: positive control for TA97a and
TA98 strains for experiments without S9; Sodium azide: positive control for TA100 and TA1535 strains for experiments without S9.
∗Values corresponding to mutagen activity.
their chemical and biological fingerprinting starting from
ethnomedical information. These research projects con-
tributed to expanding the knowledge about those plants
which are rarely or never studied but which may potentially
play a role in improving the efficacy and safety of pharma-
ceuticals and health products. Moreover, Amazonian plants
are particularly interesting since the Amazonian basin is
one of the most important biodiversity hotspots, where the
ecological conditions and the high density of species per unit
area drive the plant secondary metabolism to biosynthetic
pathways which are particularly rich in different chemical
structures [22, 23].Therefore, the present research is part of a
large project aimed to characterize the Amazonianmedicinal
flora, with particular reference to aromatic plants which
represent the largest part of the sources used in traditional
medicinal preparations. Since most of the plant species used
as traditional health remedies are characterized by flavour
and aromatic smell, the study of EOs is one of the best
strategies to draw a research profilematching biodiversity and
phytomedicine. For this reason, the chemical fingerprinting is
focused on the characterization of EOs, while the biological
activities are assayed through in vitro tests to confirm tra-
ditional properties or to find new health applications [1, 2].
Starting from these premises, the purpose of the current
research was to study the chemical characterization and
biological activities of Amazonian P. carpunya EO.
4.1. Chemical Characterization of P. carpunya Essential Oil.
As far as we know, only few papers dealt with the chemical
composition of P. carpunya EO. However, comparing our
results with those reported for P. carpunya EO from Peru
emerged important differences [7]. From a qualitative point
of view, every compound detected in the P. carpunya EO
from Peru [7] was present in our EO from Amazonian
Ecuador, but in smaller quantities. The latter obtained by
Ecuadorian plants showed the main abundance of piperitone
(26.2%), limonene (9.5%), elemicin (7.2%), 𝛽-phellandrene
(5.6%),methyleugenol (4.5), and 1,8-cineole (4.0%), while the
analogous EO obtained by Peruvian plants was reported to
contain safrole, 1,8-cineole, 𝛼-terpinene, p-cymene, spathu-
lenol and bycyclogermacrene as the terpene compounds
occurring in highest amount.These results highlight the high
plasticity of the P. carpunya species in adapting to different
environmental and allelopathic conditions, such as those of
Peru and Amazonian Ecuador, and its capacity to produce an
EO with a strongly different composition.
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4.2. Antioxidant Activity of P. carpunya Essential Oil (DPPH
Assay). The oxidative stress is generally considered the
starting point for the onset of several diseases (e.g., tis-
sues acute and chronic inflammation) usually occurring
through several complex mechanisms. Because the EO of P.
carpunya is traditionally known to be used as treatment of
generic inflammations (e.g., bronchitis, fever) [5] a prelim-
inary antioxidant evaluation has been performed through
DPPH assay. The promising results were those expressed
by P. carpunya EO, suggesting both the possible efficacy
of the traditional use of the leaves of P. carpunya as anti-
inflammatory agent and the use of the Amazonian EO in
modern preparations (e.g., antiageing products). However,
the lower IC50 value detected for P. carpunya EO than that
of the sole piperitone (and other tested pure compounds),
which means a higher bioactivity of the EO than that of
the pure compound, might indicate a possible noteworthy
bioactivity of the less abundant, or the presence of synergistic
interactions among molecules, as often demonstrated for EO
[24–26].
4.3. Synergistic Antimicrobial Activity against Candida sp.
and Time-Killing Evidences. Many plant-derived prepara-
tions used in traditional ethnomedicines have been recorded
in different pharmacopoeias as agents used to treat various
infections and more often as source of effective drugs [15,
27, 28]. In general, EOs are largely known as effective
antimicrobial agents [13, 29], but in our study the most inter-
esting evidence is given by the synergistic activity emerged
by the combination of P. carpunya EO and fluconazole as
synthetic drug. In fact, the possibility to enhance bioactivity
of health products combining natural products, such as
EOs, and synthetic drugs through synergistic interactions
gives the opportunity to reduce the amount of synthetic
active compounds, reducing at the same time their adverse
effects without limiting the therapeutic efficacy. This kind
of results obviously highly valorizes the EO of P. carpunya
from Amazonian Ecuador as possible ingredient in modern
anti-candidiasis pharmaceuticals, even more if we consider
the activity of the synergistic mixture against resistant flu-
conazole clinical isolated strains and time-killing curve that
show the dramatic reduction of microbial growth after just 2
h.
4.4. Genotoxic Safety of P. carpunya Essential Oil. To comple-
ment the awareness on the efficacy and the safe possible use
of P. carpunya EO, Ames test was carried out [17, 20]. EOs
can be used topically or orally administered and the careful
examination of possible mutagenic properties is required to
confirm and assure the safety of their use [17]. Moreover,
some evidence of possible genotoxic activities exerted by
EOs is emerging [17]. Traditional uses are by no means
warrants of safety since complex set of symptoms and cause-
effect relationships are not easily recognized and identified
by the population [17, and references therein]. Our results
pointed out the safety of the P. carpunya EO with regard to
genotoxicity, suggesting also by this aspect the potentiality of
its health uses.
5. Conclusions
The present work provides for the first time phytochemical
and biological evidence about P. carpunya EO obtained
from fresh leaves collected from plants in the Amazonian
Ecuador. The chemical characterization of the EO showed
important differences in comparison with other EOs from
the same species but from different geographical areas: these
results reflect the adapting behaviour of plants to different
environments.
The in vitro biological activities suggested, in general,
the correct traditional use of the aromatic leaves and their
preparations (e.g., topical infections remedy, such as vaginal
candidiasis), and their safety under a genotoxic point of view.
Particularly promising resulted synergistic activity emerged
with aliquots of P. carpunya EO and fluconazole, suggesting
interesting opportunities to employ the Amazonian Ecuador
EO as ingredient in anti-candidiasis products in which the
reduced amount of synthetic drug could lead to the reduction
of the possible adverse effects without compromising thera-
peutic efficacy.
Data Availability
The data used to support the findings of this study are
included within the article.
Conflicts of Interest
The authors declare no conflicts of interest.
Authors’ Contributions
Jose´ L. Ballesteros andMassimo Tacchini contributed equally
to this work.
Acknowledgments
The authors wish to thank the Salesian Polytechnic Uni-
versity of Ecuador (Center of Research and Valuation of
Biodiversity, CIVABI) for financial support. The research
was also supported by FAR2018 grant of the University
of Ferrara, grant of “Fondazione Dott. Carlo Fornasini”
(Poggio Renatico, Ferrara) (2015). This research was carried
out thanks to a bilateral cooperation agreement between
the Salesian Polytechnic University of Ecuador (Center of
Research and Valuation of Biodiversity, CIVABI) and the
University of Ferrara, Italy (Pharmaceutical biology Lab.).
References
[1] L. Scalvenzi, A. Grandini, A. Spagnoletti et al., “Myrcia splen-
dens (Sw.) DC. (syn.M. fallax (Rich.) DC.) (Myrtaceae) essen-
tial oil from amazonian Ecuador: A chemical characterization
and bioactivity profile,”Molecules, vol. 22, no. 7, article no. 1163,
2017.
[2] M. Radice, A. Pietrantoni, A. Guerrini et al., “Inhibitory effect
of Ocotea quixos (Lam.) Kosterm. and Piper aduncum L.
essential oils from Ecuador on West Nile virus infection,” Plant
10 Evidence-Based Complementary and Alternative Medicine
Biosystems - An International Journal Dealing with all Aspects of
Plant Biology, 2018.
[3] M. E. Rondo´n, J. Velasco, X. Cornejo, J. Ferna´ndez, and V.
Morocho, “Chemical composition and antibacterial activity of
Piper lenticellosum C.D.C essential oil collected in Ecuador,”
Journal of Applied Pharmaceutical Science, vol. 6, no. 8, pp. 156–
159, 2016.
[4] A. Quı´lez, B. Berenguer, G. Gilardoni et al., “Anti-secretory,
anti-inflammatory and anti-Helicobacter pylori activities of
several fractions isolated from Piper carpunya Ruiz & Pav,”
Journal of Ethnopharmacology, vol. 128, no. 3, pp. 583–589, 2010.
[5] J. L. Ballesteros, F. Bracco,M. Cerna, P. Vita Finzi, andG. Vidari,
“Ethnobotanical research at the Kutuku´ Scientific Station,
Morona-Santiago, Ecuador,” BioMed Research International,
vol. 2016, Article ID 9105746, 18 pages, 2016.
[6] P. P. Diaz, B. C. Ramos, and G. E. Matta, “New C6-C3 and
C6-C1 compounds from Piper lenticellosum,” Journal of Natural
Products, vol. 49, no. 4, pp. 690-691, 1986.
[7] L. Vargas, A. Velasco-Negueruela, M. J. Pe´rez-Alonso, J. Pala´-
Pao´l, and M. C. G. Vallejo, “Essential oil composition of the
leaves and spikes of Piper carpunya Ruı´z et Pavo´n (Piperaceae)
from Peru,” Journal of Essential Oil Research, vol. 16, no. 2, pp.
122-123, 2004.
[8] C. Trabadela, S. Sa´nchez-Fidalgo, P. Min˜o et al., “Gastroprotec-
tive effects of Piper carpunya against diclofenac-induced gastric
lesions in rats,” Pharmaceutical Biology, vol. 46, no. 12, pp. 829–
837, 2008.
[9] H. I. Bax, I. A. J. M. Bakker-Woudenberg, C. P. de Vogel, A. van
der Meijden, A. Verbon, and J. E. M. de Steenwinkel, “The role
of the time-kill kinetics assay as part of a preclinical modeling
framework for assessing the activity of anti-tuberculosis drugs,”
Tuberculosis, vol. 105, pp. 80–85, 2017.
[10] K. M. Park, J. S. You, H. Y. Lee, N. I. Baek, J. K. Hwang, and G.
Kuwanon, “An antibacterial agent from the root bark ofMorus
alba against oral pathogens,” Journal of Ethnopharmacology, vol.
84, no. 2-3, pp. 181–185, 2003.
[11] D. M. Maron and B. N. Ames, “Revised methods for the
Salmonella mutagenicity test,” Mutation Research, vol. 113, no.
3-4, pp. 173–215, 1983.
[12] R. P. Adams, Identification of Essential Oil Components by Gas
- Chromatography / Quadrupole Mass Spectrometry, Allured,
Carol Stream IL, USA, 2007.
[13] F. Bakkali, S. Averbeck, D. Averbeck, and M. Idaomar, “Bio-
logical effects of essential oils—a review,” Food and Chemical
Toxicology, vol. 46, no. 2, pp. 446–475, 2008.
[14] A. Guerrini, D. Rossi, A. Grandini et al., “Biological and chemo-
diverse characterization of Amazonian (Ecuador) Citrus petit-
grains,” Journal of Applied Botany and Food Quality, vol. 87, pp.
108–116, 2014.
[15] Z. Cheng, J.Moore, and L. Yu, “High-throughput relativeDPPH
radical scavenging capacity assay,” Journal of Agricultural and
Food Chemistry, vol. 54, no. 20, pp. 7429–7436, 2006.
[16] F. Ariffin, S. Heong Chew, K. Bhupinder, A. A. Karim, and
N. Huda, “Antioxidant capacity and phenolic composition of
fermented Centella asiatica herbal teas,” Journal of the Science
of Food and Agriculture, vol. 91, no. 15, pp. 2731–2739, 2011.
[17] A. Guerrini, G. Sacchetti, D. Rossi et al., “Bioactivities of Piper
aduncum L. and Piper obliquum Ruiz & Pavon (Piperaceae)
essential oils from Eastern Ecuador,” Environmental Toxicology
and Pharmacology, vol. 27, no. 1, pp. 39–48, 2009.
[18] K. Zaidi, F. Shah, R. Parmar, and V. Thawani, “Anticandidal
synergistic activity of Ocimum sanctum and fluconazole of
azole resistance strains of clinical isolates,” Journal de Mycologie
Me´dicale, vol. 28, no. 2, pp. 289–293, 2018.
[19] E. J. Ernst, M. E. Klepser, M. E. Ernst, S. A. Messer, and M.
A. Pfaller, “In vitro pharmacodynamic properties of MK-0991
determined by time-kill methods,”Diagnostic Microbiology and
Infectious Disease, vol. 33, no. 2, pp. 75–80, 1999.
[20] D. Rossi, A. Guerrini, S. Maietti et al., “Chemical fingerprinting
and bioactivity of Amazonian Ecuador Croton lechleri Mu¨ll.
Arg. (Euphorbiaceae) stem bark essential oil: a new functional
food ingredient?” Food Chemistry, vol. 126, no. 3, pp. 837–848,
2011.
[21] A. Spagnoletti, A. Guerrini, M. Tacchini et al., “Chemical
composition and bio-efficacy of essential oils from Italian
aromatic plants: Mentha suaveolens, Coridothymus capitatus,
Origanum hirtum and Rosmarinus officinalis,” Natural Product
Communications (NPC), vol. 11, no. 10, pp. 1517–1520, 2016.
[22] G. Sacchetti, S. Maietti, M. Muzzoli et al., “Comparative
evaluation of 11 essential oils of different origin as functional
antioxidants, antiradicals and antimicrobials in foods,” Food
Chemistry, vol. 91, no. 1, pp. 621–632, 2005.
[23] D. Rossi, A. Guerrini, G. Paganetto et al., “Croton lechleri
Mu¨ll. Arg. (Euphorbiaceae) stem bark essential oil as pos-
sible mutagen-protective food ingredient against heterocyclic
amines from cooked food,” Food Chemistry, vol. 139, no. 1–4,
pp. 439–447, 2013.
[24] A. Chrysargyris, P. Xylia, G. Botsaris, and N. Tzortzakis,
“Antioxidant and antibacterial activities, mineral and essential
oil composition of spearmint (Mentha spicata L.) affected by the
potassium levels,” Industrial Crops and Products, vol. 103, pp.
202–212, 2017.
[25] A. L. Urbizu-Gonza´lez, O. Castillo-Ruiz, G. C. G. Mart´ınez-
A´vila, and J. A. Torres-Castillo, “Natural variability of essential
oil and antioxidants in the medicinal plant Turnera diffusa,”
Asian Pacific Journal of Tropical Medicine, vol. 10, no. 2, pp. 121–
125, 2017.
[26] A. Guerrini, G. Sacchetti, M. Muzzoli et al., “Composition of
the volatile fraction of Ocotea bofo Kunth (Lauraceae) calyces
by GC-MS and NMR fingerprinting and its antimicrobial
and antioxidant activity,” Journal of Agricultural and Food
Chemistry, vol. 54, no. 20, pp. 7778–7788, 2006.
[27] J. Meletiadis, S. Pournaras, E. Roilides, and T. J. Walsh,
“Defining fractional inhibitory concentration index cutoffs for
additive interactions based on self-drug additive combinations,
MonteCarlo simulation analysis, and in vitro-in vivo correlation
data for antifungal drug combinations against Aspergillus fumi-
gatus,” Antimicrobial Agents and Chemotherapy, vol. 54, no. 2,
pp. 602–609, 2010.
[28] M. Turgis, K. D. Vu, C. Dupont, and M. Lacroix, “Combined
antimicrobial effect of essential oils and bacteriocins against
foodborne pathogens and food spoilage bacteria,”FoodResearch
International, vol. 48, no. 2, pp. 696–702, 2012.
[29] S. K. Filoche, K. Soma, and C. H. Sissons, “Antimicrobial effects
of essential oils in combinationwith chlorhexidine digluconate,”
Oral Microbiology and Immunology, vol. 20, no. 4, pp. 221–225,
2005.
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
